



CareDx Testing Solutions for Heart Transplant Recipients

- The published peer-reviewed data supports the guidance that AlloSure Heart may be used in a broad range of patients, including patients of varying risk profiles, ethnic demographics, and immunologic risk profiles. ([Khush, et al.](#))
- There is sufficient evidence to use AlloSure Heart for surveillance and for cause. ([Khush, et al.](#))
- In an independent study published by Alam et al., the sensitivity and specificity to detect histological evidence of rejection for AlloSure Heart at a cutoff of 0.2% was 96% and 66% respectively. ([Alam, et al.](#))
- In 3 recent real-world studies evaluating HeartCare, investigators were able to document a significant reduction in biopsies without an increase in adverse events when AlloSure Heart was combined with AlloMap® Heart. The reduction in biopsies ranged from 12.7% to 55%. ([Gondi, et al.](#); [Henricksen, et al.](#); and [Amadio, et al.](#))
- In Amadio et al., the authors documented that in 42% of patients, immunosuppressive therapy could be safely reduced by managing patients with AlloSure and AlloMap and without biopsies. ([Amadio, et al.](#))
- In the pediatric clinical utility study by Feingold et al., AlloSure Heart alone facilitated the reduction in immunosuppression including the transition to calcineurin free regimens. ([Feingold, et al.](#))

[full bibliography available on our website](#)